Quantcast
Last updated on April 18, 2014 at 17:20 EDT

Latest Coyote Pharmaceuticals Inc. Stories

2013-02-13 12:27:08

MENLO PARK, Calif., Feb. 13, 2013 /PRNewswire/ -- Coyote Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on neurodegenerative diseases, announced today that it has initiated the GMP manufacturing process for CNS-102 following its recent pre-IND meeting with the Food and Drug Administration (FDA). CNS-102 is being developed initially to treat amyotrophic lateral sclerosis (ALS). In its meeting with the FDA, Coyote was advised to apply for Fast Track designation when it...

2013-01-02 12:22:25

MENLO PARK, Calif., Jan. 2, 2013 /PRNewswire/ -- Coyote Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on neurodegenerative diseases, announced today that President and CEO, Hiroaki Serizawa, Ph.D. will present at the Biotech Showcase(TM) 2013 Conference being held in San Francisco January 7-9, 2013. Dr. Serizawa will provide an overview of the company's lead compound, CNS-102, which will soon enter clinical development for amyotrophic lateral sclerosis (ALS) and...

2012-10-01 06:26:22

MENLO PARK, Calif., Oct. 1, 2012 /PRNewswire/ -- Coyote Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on orphan and neurodegenerative diseases, today announced that it is moving forward with a "dual-track" clinical program for its lead compound, CNS-102, for treating Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease (AD). The first phase of the clinical program, targeting ALS, is set to commence in 2013. "Neurodegenerative disorders, including ALS,...